Fluconazole in the treatment of pulmonary zygomycosis

Simple item page
dc.contributor.authorKoszyca, B.
dc.contributor.authorEllis, D.
dc.contributor.authorToogood, I.
dc.contributor.authorByard, R.
dc.date.issued1995
dc.description.abstractPulmonary zygomycosis is an aggressive, often terminal infection that may be found in patients who are immunocompromised as a result of cytotoxic chemotherapy. Conventional treatment is by surgical debridement augmented with high-dose intravenous amphotericin B, but even with such treatment the course is usually fulminant with a high mortality rate. Recent work has suggested that the new antifungal triazole, fluconazole, may be of benefit in treating zygomycete infection. The case of a 15-year-old boy who developed pulmonary zygomycosis while on chemotherapy for acute lymphoblastic leukaemia, and who survived for 11 months with oral fluconazole therapy alone, is supportive of this proposal.
dc.identifier.citationMycoses, 1995; 38(7-8):277-280
dc.identifier.doi10.1111/j.1439-0507.1995.tb00407.x
dc.identifier.issn0933-7407
dc.identifier.issn1439-0507
dc.identifier.orcidEllis, D. [0000-0002-7283-4667]
dc.identifier.orcidByard, R. [0000-0002-0524-5942]
dc.identifier.urihttp://hdl.handle.net/2440/11667
dc.language.isoen
dc.publisherBlackwell
dc.source.urihttps://doi.org/10.1111/j.1439-0507.1995.tb00407.x
dc.subjectZygomycosis
dc.subjectpulmonary mycosis
dc.subjectacute lymphoblastic leukaemia
dc.subjectfluconazole
dc.titleFluconazole in the treatment of pulmonary zygomycosis
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Microbiology and Immunology publications